



Title	Favorable effect of sodium–glucose cotransporter 2 inhibitor, dapagliflozin, on non alcoholic fatty liver disease compared with pioglitazone
Author(s)	Cho, Kyu Yong; Nakamura, Akinobu; Omori, Kazuno; Takase, Takahiro; Miya, Aika; Yamamoto, Kohei; Nomoto, Hiroshi; Kameda, Hiraku; Taneda, Shinji; Kurihara, Yoshio; Aoki, Shin; Atsumi, Tatsuya; Miyoshi, Hideaki
Citation	Journal of Diabetes Investigation, 12(7), 1272-1277 https://doi.org/10.1111/jdi.13457
Issue Date	2021-07-08
Doc URL	http://hdl.handle.net/2115/82892
Rights(URL)	http://creativecommons.org/licenses/by-nc/4.0/
Type	article
File Information	JDI 12 1272-1277.pdf



[Instructions for use](#)

Favorable effect of sodium–glucose cotransporter 2 inhibitor, dapagliflozin, on non-alcoholic fatty liver disease compared with pioglitazone

Kyu Yong Cho^{1,2} , Akinobu Nakamura¹ , Kazuno Omori¹ , Takahiro Takase¹ , Aika Miya¹ , Kohei Yamamoto¹, Hiroshi Nomoto¹ , Hiraku Kameda¹ , Shinji Taneda³, Yoshio Kurihara⁴, Shin Aoki⁵, Tatsuya Atsumi¹, Hideaki Miyoshi^{1,6*}

¹Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ²Clinical Research and Medical Innovation Center, Hokkaido University Hospital, Sapporo, Japan, ³Diabetes Center, Manda Memorial Hospital, Sapporo, Japan, ⁴Kurihara Clinic, Sapporo, Japan, ⁵Aoki Clinic, Sapporo, Japan, and ⁶Division of Diabetes and Obesity, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan

Keywords

Fatty liver, Sodium–glucose cotransporter 2 inhibitor, Type 2 diabetes

*Correspondence

Hideaki Miyoshi
 Tel.: +81-11-706-8192
 Fax: +81-11-706-8194
 E-mail address:
 hmiyoshi@med.hokudai.ac.jp

J Diabetes Investig 2021; 12: 1272–1277

doi: 10.1111/jdi.13457

Clinical Trial Registry

University Hospital Medical Information Network Center Clinical Trials Registry UMIN000022804

ABSTRACT

Aims/Introduction: Sodium–glucose cotransporter 2 inhibitors, as well as thiazolidines, suppress nonalcoholic fatty liver disease (NAFLD); however, few comparative studies have been reported. Dapagliflozin has shown non-inferiority compared with pioglitazone for glycemic control, and superiority regarding weight reduction in patients with type 2 diabetes. We carried out a secondary analysis for the favorable effects of sodium–glucose cotransporter inhibitors for NAFLD.

Materials and Methods: In this multicenter, open-label, prospective, randomized, parallel-group comparison trial, patients taking pioglitazone for ≥ 12 weeks were randomly switched to dapagliflozin or continued pioglitazone for a further 24 weeks. The fatty liver index (FLI), consisting of body mass index, triglycerides, waist circumference and γ -glutamyl transpeptidase, was used for the evaluation of NAFLD.

Results: A total of 53 participants with NAFLD (27 dapagliflozin; 26 pioglitazone) were included in this analysis. FLI decreased significantly in the dapagliflozin group (48.7 ± 23.4 to 42.1 ± 23.9) compared with the pioglitazone group (49.0 ± 26.1 to 51.1 ± 25.8 ; $P < 0.01$). Multiple linear regression analysis showed that the changes in FLI had a significantly positive correlation with changes in glycated hemoglobin ($P = 0.03$) and insulin level ($P < 0.01$) in the dapagliflozin group.

Conclusion: Dapagliflozin might be more beneficial than pioglitazone in patients with NAFLD. Improvements in FLI would be closely related to glycemic control.

INTRODUCTION

Diabetes treatments aim to extend life expectancy and improve patient quality of life by suppressing the onset and progression of diabetic complications. Although macro- and microvascular diseases are the main targets of prevention, non-alcoholic fatty liver disease (NAFLD) is also a common and clinically significant complication. NAFLD includes non-alcoholic fatty liver, which refers to steatosis affecting hepatocytes, and non-alcoholic steatohepatitis, mainly involving inflammation and

fibrosis, and might progress ultimately to cirrhosis and hepatocellular carcinoma¹. In addition to various disorders, including hypertension, dyslipidemia and metabolic syndrome, suggested as related etiological factors of NAFLD, insulin resistance based on hyperinsulinemia also requires appropriate therapeutic interventions². Type 2 diabetes frequently coexists with NAFLD, and is an independent risk factor for the development of cirrhosis and liver cancer^{3,4}. The thiazolidine, pioglitazone (PIO), has been shown to be a useful treatment for NAFLD in patients with type 2 diabetes, and has been widely used to improve insulin resistance and NAFLD⁵. Sodium–glucose cotransporter 2 (SGLT2) inhibitors have also recently been

Received 10 September 2020; revised 21 October 2020; accepted 30 October 2020

reported to improve NAFLD^{5–8}; however, their efficacy in NAFLD has not been proven in large-scale, placebo-controlled studies, and few comparative studies with other antidiabetic drugs have been reported. We recently determined the non-inferiority of dapagliflozin (DAP) for glycemic control, and superiority in terms of weight reduction compared with PIO in patients with type 2 diabetes⁹; bodyweight was dramatically reduced (–4.2 kg in 24 weeks) by switching from PIO to DAP. In the current study, we aimed to compare the efficacies of DAP and PIO in patients with NAFLD.

METHODS

Study overview

The present study was a secondary analysis of our original multicenter, open-label, prospective, randomized, parallel-group comparison trial⁹. All patients provided written informed consent before enrollment. The detailed rationale and protocol of the original trial have been described previously⁹, and are summarized below. Eligible participants included patients with type 2 diabetes mellitus, aged 20–80 years, 6.5–8.5% of glycated hemoglobin (HbA1c), ≥ 23 kg/m² of body mass index (BMI), estimated glomerular filtration rate ≥ 45 mL/min/1.73 m² and treatment with PIO for >12 weeks undergoing outpatient treatment at seven sites in Hokkaido, Japan. Patients continued with PIO or were switched to DAP for 24 weeks.

Patients who were habitual drinkers were excluded from this secondary analysis. The extent of fatty liver was estimated using the fatty liver index (FLI), consisting of BMI, triglycerides (TG), waist circumference (WC) and γ -glutamyl transpeptidase (γ -GTP), using the following equation: $FLI = \{ \exp(0.953 \times \log(TG) + 0.139 \times BMI + 0.718 \times \log(\gamma\text{-GTP}) + 0.053 \times WC - 15.745) / 1 + \exp(0.953 \times \log(TG) + 0.139 \times BMI + 0.718 \times \log(\gamma\text{-GTP}) + 0.053 \times WC - 15.745) \} \times 100$ ¹⁰. Participants with an FLI <30 were excluded from the analysis, because FLI <30 can be used to rule out hepatic steatosis. The Fibrosis-4 (FIB-4) index, as a marker of hepatic fibrosis, was derived as follows: $FIB-4 = \text{age} \times (\text{aspartate aminotransferase [AST]} / (\text{platelet count} \times [\text{alanine aminotransferase (ALT)}]^{1/2}))$ ¹¹.

The present study was registered with the University Hospital Medical Information Network Center Clinical Trials Registry (UMIN000022804), and the protocol was approved by the institutional review board at Hokkaido University Hospital Clinical Research and Medical Innovation Center (016-0042). The study was carried out in accordance with the Declaration of Helsinki and its amendments.

Statistical analysis

The results are expressed as the mean \pm standard deviation, median (range) or number (%). Differences in baseline characteristics between the two groups were evaluated using unpaired *t*-tests or Mann–Whitney *U*-tests for continuous variables, and χ^2 -tests or Fisher's exact tests for categorical variables. Correlation coefficients and simple linear regression analyses were used

to test for associations between variables. Multivariate analyses were carried out using multiple linear regression to identify factors independently associated with the outcomes. FLI components and their related factors (bodyweight, TG, WC and γ -GTP) were excluded from the multiple linear regression analysis. The results within each group were compared by paired-sample *t*-tests or Wilcoxon's signed-rank tests. Data were analyzed using JMP Pro v14.1.1 software (SAS Institute, Cary, NC, USA), and values of $P < 0.05$ were considered statistically significant.

RESULTS

Characteristics of the participants

A total of 71 patients were randomly assigned to the DAP group ($n = 36$) or PIO group ($n = 35$). All participants had completed the original randomized, controlled trial and their baseline characteristics have been reported previously⁹. Five patients in the DAP group and two patients in the PIO group were excluded from the present analysis because of habitual drinking, and four patients in the DAP group and seven patients in the PIO group were excluded because their FLI was <30. A total of 27 patients were finally included in the DAP group and 26 in the PIO group (Figure 1). There was no significant difference in baseline patient characteristics, including lipid profiles and liver enzymes, between the two groups. However, bodyweight and plasma insulin levels after 24 weeks decreased significantly more in the DAP group compared with the PIO group (Table 1). Only one patient in the DAP group had a decreased sulfonylurea dose during follow up, but the change was not significant.

Changes in FLI and identification of independent predictors

FLI decreased significantly more in the DAP group (58.3 ± 18.3 to 48.8 ± 19.5) compared with the PIO group (58.4 ± 20.6 to 61.2 ± 20.8) after 24 weeks ($P < 0.01$;




Figure 1 | Flow chart of study participants in this analysis. DAP, dapagliflozin; FLI, fatty liver index; PIO, pioglitazone.

Table 1 | Clinical characteristics and variables in patients treated with dapagliflozin and pioglitazone

	DAP (n = 27)		PIO (n = 26)		P
Age (years)	63.5 ± 7.1		63.4 ± 10.2		0.96
Male, n (%)	15 (55.6)		13 (50.0)		0.59
	0W	24W	0W	24W	
Bodyweight (kg)	75.1 ± 15.8	70.9 ± 16.0**	74.6 ± 13.8	75.1 ± 14.1	<0.01
WC (cm)	99.3 ± 7.9	95.8 ± 8.2**	101.5 ± 8.6	102.4 ± 10.0	0.02
FPG (mmol/L)	7.2 ± 1.2	7.3 ± 1.3	7.0 ± 1.1	7.4 ± 1.4	0.82
HbA1c (%)	6.8 ± 0.6	7.0 ± 0.8	6.9 ± 0.7	7.1 ± 0.8	0.58
Insulin (μU/mL)	5.8 (3.6–7.0)	5.5 (4.0–6.9)	5.0 (3.3–6.6)	5.6 (4.1–8.5)*	0.02
TC (mg/dL)	175.5 (150.8–199.8)	182.0 (165.3–199.3)	168.5 (151.8–196.0)	175.5 (158.0–193.5)	0.78
LDL-C (mg/dL)	95.5 (82.8–104.0)	97.0 (83.3–12.0)	90.5 (78.5–112.3)	96.0 (81.8–106.3)	0.71
HDL-C (mg/dL)	56.0 (48.8–69.3)	54.0 (46.8–68.8)	54.5 (47.0–65.0)	55.0 (46.8–64.5)	0.53
TG (mg/dL)	108.0 (77.3–134.8)	104.5 (79.8–151.0)	94.5 (58.3–151.3)	103.0 (77.5–164.0)	0.72
AST (IU/L)	23.0 ± 12.0	21.4 ± 10.6	23.6 ± 6.9	23.2 ± 6.5	0.25
ALT (IU/L)	23.1 ± 14.1	21.3 ± 12.4	23.7 ± 12.2	22.3 ± 10.5	0.83
γ-GTP (IU/L)	25.9 ± 15.5	25.2 ± 10.6	23.8 ± 11.2	24.1 ± 11.9	0.48

P-value: mean changes from baseline of the study (0W) to 24 weeks (end of the study; 24W) between the dapagliflozin (DAP) and pioglitazone (PIO) groups, unpaired *t*-tests or Mann–Whitney *U*-tests. **P* < 0.05 and ***P* < 0.01 between 0W to 24W, paired *t*-tests or Wilcoxon's signed rank test. γ-GTP, γ-glutamyl transpeptidase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; HDL-C, high density lipoprotein-cholesterol; LDL-C, low density lipoprotein-cholesterol; TC, total cholesterol; TG, triglycerides; WC, waist circumference.

Figure 2). Changes in FLI in the DAP group were significantly positively correlated with changes in HbA1c, insulin, homeostasis model assessment as an index of insulin resistance and total cholesterol, whereas changes in the PIO group were positively correlated with changes in ALT and negatively correlated with changes in high-density lipoprotein (HDL)-cholesterol (Table 2). Furthermore, multiple linear regression analysis showed that changes in HbA1c and insulin were significantly positively correlated with changes in FLI in the DAP group (Table 3), but the relationships with ALT and HDL in the PIO group were no longer significant. The FIB-4 index was significantly decreased in the DAP group (1.37 ± 0.59 to 1.20 ± 0.50) compared with the PIO group (1.32 ± 0.50 to 1.35 ± 0.52 ; *P* < 0.01; Figure 3). Furthermore, there were no predictors for changes in the FIB-4 index. The change in the aspartate aminotransferase : ALT ratio showed no difference between the two groups (DAP, 1.09 ± 0.33 – 1.09 ± 0.35 ; PIO, 1.09 ± 0.31 – 1.14 ± 0.32).

DISCUSSION

This secondary analysis of our previous randomized, controlled trial showed that DAP ameliorated FLI, as a surrogate measure for fatty liver, compared with PIO in patients with type 2 diabetes complicated by NAFLD. The change in FLI in patients treated with DAP was significantly positively correlated with changes in insulin and HbA1c, in accordance with previous reports^{6,7}. Elevated plasma glucose and insulin levels promote fatty acid synthesis, and influence the development of hepatic steatosis¹². DAP is a rational treatment for improving hepatic steatosis by improving glucose metabolism and reducing




Figure 2 | Changes in fatty liver index between 0 and 24 weeks. White circles are the mean ± standard deviation. ***P* < 0.01 between the dapagliflozin (DAP) and pioglitazone (PIO) groups, unpaired *t*-tests; ##*P* < 0.01 between 0 and 24 weeks in each group, paired *t*-tests. 0W, baseline of the study; 24W, 24 weeks (end of the study).

hepatic lipogenesis, related to lower insulin levels. In addition to improving glycemic control and hyperinsulinemia, SGLT2 inhibitors can also slow or even reverse the progression of NAFLD as a result of their beneficial effects on insulin resistance through weight loss, especially visceral fat¹³, associated

Table 2 | Relationships between changes in fatty liver index and clinical parameters

	DAP		PIO	
	Correlation coefficient	P	Correlation coefficient	P
ΔFPG	0.0586	0.74	0.1867	0.31
ΔHbA1c	0.3493	0.04	0.2569	0.16
ΔInsulin	0.4244	0.03	0.0379	0.85
ΔHOMA-IR	0.4237	0.03	0.0287	0.89
ΔTC	0.3590	0.04	0.0872	0.64
ΔHDL-C	-0.1238	0.49	-0.3877	0.03
ΔLDL-C	0.1075	0.55	0.0541	0.77
ΔAST	0.0114	0.95	0.1510	0.41
ΔALT	0.1872	0.29	0.3647	0.04

ALT, alanine aminotransferase; AST, aspartate aminotransferase; DAP, dapagliflozin; PG, fasting plasma glucose; HbA1c, glycated hemoglobin; HDL-C, high density lipoprotein-cholesterol; HOMA-IR, homeostasis model assessment as an index of insulin resistance; LDL-C, low density lipoprotein-cholesterol; PIO, pioglitazone; TC, total cholesterol.

Table 3 | Relationships between changes in fatty liver index and clinical parameters in the dapagliflozin group according to multiple linear regression analysis

	Regression coefficients	95% CI	P
ΔInsulin	1.31	0.38, 2.14	<0.01
ΔHbA1c	7.32	0.38, 4.26	0.03
ΔTC	0.02	-0.15, 0.19	0.86

Multiple linear regression was adjusted for age, sex, insulin, glycated hemoglobin (HbA1c) and total cholesterol (TC). 95% CI, 95% confidence interval.

with hepatic inflammation leading to exacerbation of NAFLD¹⁴.

Furthermore, DAP improved the FIB-4 index, as a marker of liver fibrosis. PIO was shown to improve fibrosis in a rodent model and meta-analysis; however, the Pioglitazone, Vitamin E or Placebo of Non-Alcoholic Steatohepatitis (PIVENS) trial, which was the first to show a convincing histological benefit in patients with non-alcoholic steatohepatitis, did not show any improvement of fibrosis in patients treated with PIO^{15,16}. In contrast, SGLT2 inhibitors improved hepatic fibrosis in terms of both pathological examination¹⁷ and surrogate markers⁸. The mechanism of SGLT2 inhibitors, which improves liver fibrosis, has not been fully elucidated. However, there is histological evidence that treatment with SGLT2 inhibitors improves liver fibrosis in mouse models of non-alcoholic steatohepatitis and diabetes, which suggests that administration of SGLT2 inhibitors prevents the progression of liver fibrosis by reducing inflammation in the liver¹⁸. SGLT2 inhibitors have thus been suggested to improve a wider range of NAFLD characteristics, including fibrosis and inflammation.




Figure 3 | Changes in the Fibrosis 4 index between 0 and 24 weeks. White circles are the mean ± standard deviation. **P* < 0.05 between the dapagliflozin (DAP) and pioglitazone (PIO) groups, unpaired *t*-tests; #*P* < 0.05 between 0 and 24 weeks in each group, paired *t*-tests. 0W, baseline of the study; 24W, 24 weeks (end of the study).

Only one previous study has compared the efficacies of SGLT2 inhibitors and PIO on NAFLD in patients with type 2 diabetes¹⁹. In that report, ipragliflozin exerted similar beneficial effects to PIO, based on the liver : spleen attenuation ratio on computed tomography. The apparent discrepancy between these and the current results might be caused by differences in the study designs and evaluation methods. The previous study started both medications additively at the same time, whereas the present study switched from PIO to DAP, and NAFLD in our participants was therefore likely to have been improved to some extent by PIO before the start of the study. Interestingly, the previous study reported that the marked improvement in serum adiponectin levels produced by PIO ameliorated NAFLD¹⁹. Adiponectin decreases hepatic and systematic insulin resistance, and attenuates liver inflammation and fibrosis²⁰. In the PIO group of this study, improved FLI was associated with elevated HDL. Adiponectin increases HDL cholesterol by promoting reverse transport of cholesterol. The association of the changes in HDL and NAFLD might suggest the involvement of adiponectin²¹. The main mechanism underlying the amelioration of NAFLD by SGLT2 inhibitors is probably due to lower circulating glucose and insulin levels; however, adiponectin might also be involved, given that bodyweight was reduced in the DAP group, and SGLT2 inhibitors have been reported to increase adiponectin levels^{22,23}. Unfortunately, we did not have a chance to measure adiponectin during this study, and the relationship therefore was not investigated.

The present analysis had two main limitations. It was a secondary analysis and might therefore have lacked statistical strength. However, approximately 75% of the participants from the original randomized, controlled trial were included in this analysis, and their backgrounds were matched. In addition, NAFLD was evaluated indirectly by calculating FLI, and pathological examination, as the standard method for measuring liver steatosis and fibrosis, was not carried out. FLI is a value calculated by BMI, WC, TG, and γ -GTP, and it was difficult to evaluate the relationship between FLI and these individual factors. A further randomized, comparative trial of SGLT2 inhibitors versus PIO, based on pathophysiological examination, is therefore required.

In conclusion, DAP might ameliorate NAFLD compared with PIO, and improvements in FLI as a result of DAP treatment might depend on glycemic control.

ACKNOWLEDGMENTS

The authors thank Naoki Nishimoto PhD for advice on statistical analysis, and Susan Furness PhD from Edanz Group (<https://en-author-services.edanzgroup.com/ac>) for editing a draft of this manuscript. This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors.

DISCLOSURE

A Nakamura, SN Taneda, Y Kurihara, T Atsumi and H Miyoshi have received honoraria for lectures, and received research funding from some organizations as described below. A Nakamura obtained research support from Mitsubishi Tanabe Pharma Co., Daiichi Sankyo Co. Ltd., MSD, Novo Nordisk Pharma, Novartis Pharma, AstraZeneca, LifeScan Japan and Taisho Pharmaceutical. S Taneda received honoraria for lectures from Takeda Pharmaceutical Co., Ltd., Novo Nordisk Pharma and Ono Pharmaceutical Co., Ltd. Y Kurihara received honoraria for lectures from AstraZeneca, Mitsubishi Tanabe Pharma Co., Ltd., MSD, Ono Pharmaceutical Co., Ltd., Sanofi, Taisho Pharmaceutical Co., Ltd., Kowa Pharmaceutical Co. Ltd., Eli Lilly, Sumitomo Dainippon pharma Co. and Takeda Pharmaceutical Co., Ltd. T Atsumi received honoraria for lectures from Mitsubishi Tanabe Pharma Co., Chugai Pharmaceutical Co., Ltd., Astellas Pharma Inc., Takeda Pharmaceutical Co., Ltd., Pfizer Inc., AbbVie Inc., Eisai Co. Ltd., Daiichi Sankyo Co. Ltd., Bristol-Myers Squibb Co., UCB Japan Co. Ltd. and Eli Lilly Japan K.K., and received research funding from Astellas Pharma Inc., Takeda Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Co., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co. Ltd., Otsuka Pharmaceutical Co., Ltd., Pfizer Inc. and Alexion Inc. H Miyoshi received honoraria for lectures from Astellas Pharma Inc., AstraZeneca, Sumitomo Dainippon Pharma Co, Eli Lilly, Kissei, Mitsubishi Tanabe Pharma Co., MSD, Novartis Pharma, Novo Nordisk Pharma, Takeda Pharmaceutical Co., Ltd., Kowa Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd. and Sanofi, and received

research funding from Astellas Pharma Inc., AstraZeneca, Daiichi Sankyo Co. Ltd., Sumitomo Dainippon Pharma Co., Eli Lilly, Mitsubishi Tanabe Pharma Co., MSD, Novo Nordisk Pharma, Sanofi, Takeda Pharmaceutical Co., Ltd., Kowa Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd. and Taisho Toyama Pharmaceutical Co., Ltd. The other authors declare no conflict of interest.

REFERENCES

1. Browning JD, Szczepaniak LS, Dobbins R, *et al.* Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. *Hepatology* 2004; 40: 1387–1395.
2. Gusdon AM, Song KX, Qu S. Nonalcoholic fatty liver disease: pathogenesis and therapeutics from a mitochondria-centric perspective. *Oxid Med Cell Longev* 2014; 2014: 1–20.
3. Bazick J, Donithan M, Neuschwander-Tetri BA, *et al.* Clinical model for NASH and advanced fibrosis in adult patients with diabetes and NAFLD: guidelines for referral in NAFLD. *Diabetes Care* 2015; 38: 1347–1355.
4. Kawamura Y, Arase Y, Ikeda K, *et al.* Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma. *Am J Gastroenterol* 2012; 107: 253–261.
5. Belfort R, Harrison SA, Brown K, *et al.* A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. *N Engl J Med* 2006; 355: 2297–2307.
6. Takase T, Nakamura A, Miyoshi H, *et al.* Amelioration of fatty liver index in patients with type 2 diabetes on ipragliflozin: an association with glucose-lowering effects. *Endocr J* 2017; 64: 363–367.
7. Yamauchi Y, Nakamura A, Takahashi K, *et al.* Factors with remission of fatty liver in patients with type 2 diabetes treated with ipragliflozin. *Endocr J* 2019; 66: 995–1000.
8. Shimizu M, Suzuki K, Kato K, *et al.* Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease. *Diabetes Obes Metab* 2019; 21: 285–292.
9. Cho KY, Nakamura A, Omori K, *et al.* Effect of switching from pioglitazone to the sodium glucose co-transporter-2 inhibitor dapagliflozin on body weight and metabolism-related factors in patients with type 2 diabetes mellitus: an open-label, prospective, randomized, parallel-group comparison trial. *Diabetes Obes Metab* 2019; 21: 710–714.
10. Bedogni G, Bellentani S, Miglioli L, *et al.* The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. *BMC Gastroenterol* 2006; 6: 33.
11. Sterling RK, Lissen E, Clumeck N, *et al.* Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. *Hepatology* 2006; 43: 1317–1325.
12. Postic C, Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons

- from genetically engineered mice. *J Clin Investig* 2008; 118: 829–838.
13. Yamamoto C, Miyoshi H, Ono K, *et al*. Ipragliflozin effectively reduced visceral fat in Japanese patients with type 2 diabetes under adequate diet therapy. *Endocr J* 2016; 63: 589–596.
 14. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. *Hepatology* 2010; 52: 1836–1846.
 15. Rinella ME. Nonalcoholic fatty liver disease: a systematic review. *JAMA* 2015; 313: 2263–2273.
 16. Sanyal AJ, Chalasani N, Kowdley KV, *et al*. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. *N Engl J Med* 2010; 362: 1675–1685.
 17. Seko Y, Nishikawa T, Umemura A, *et al*. Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis. *Diabetes Metab Syndr Obes* 2018; 11: 835–843.
 18. Jojima T, Tomotsune T, Iijima T, *et al*. Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes. *Diabetol Metab Syndr* 2016; 8: 45.
 19. Ito D, Shimizu S, Inoue K, *et al*. Comparison of ipragliflozin and pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes: a randomized, 24-week, open-label, active-controlled trial. *Diabetes Care* 2017; 40: 1364–1372.
 20. Polyzos SA, Kountouras J, Zavos C, *et al*. The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease. *Diabetes Obes Metab* 2010; 12: 365–383.
 21. Ryo M, Nakamura T, Kihara S, *et al*. Adiponectin as a biomarker of the metabolic syndrome. *Circ J* 2004; 68: 975–981.
 22. Garvey TW, Van Gaal L, Leiter LA, *et al*. Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes. *Metabolism* 2018; 85: 32–37.
 23. Tobita H, Sato S, Miyake T, *et al*. Effects of dapagliflozin on body composition and liver tests in patients with nonalcoholic steatohepatitis associated with type 2 diabetes mellitus: a prospective, open-label, uncontrolled study. *Curr Ther Res Clin Exp* 2017; 87: 13–19.